Relationship Between Adverse Drug Reactions and Unlicensed/ Off-label Drug Use in Hospitalized Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6227 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Medications are the most commonly used clinical intervention and complications associated with their use are one of the most common causes of adverse events in health care. Adverse Drug Reactions (ADR) are a major cause of morbidity and pose a substantial burden on limited health care resources.

Many drugs used to treat children in hospitals are either not licensed for use in children or are prescribed outside the terms of their product license (off-label prescribing). This is mainly due to the lack of clinical trials in this vulnerable population, and both practical difficulties and ethical considerations arising from involving children in clinical research.

Drugs used within the specifications of the product license might be less likely to cause ADR compared to drugs that are either unlicensed or off-label for use in children. Few studies have shown a significant association between pediatric off-label drug use and ADR.

To compare the probability of ADR after a licensed drug prescription versus the probability of ADR after prescribing a drug off-label in children, we are conducting a multi-center prospective observational study in different pediatric hospital wards in France.

The availability of electronic health records made this study feasible. An automatic data extraction from hospital information systems has been implemented. A computer algorithm for determining pediatric drug labelling (i.e. off-label or unlicensed use) using the French summaries of product characteristics available in Thériaque® database has been developed. Detection of ADRs is carried out by health care professionals and research groups using a trigger tool and patients' electronic health records. The causality between ADRs and suspected medications is evaluated using the Naranjo and the French methods by regional pharmacovigilance centers. An independent pharmacovigilance board validates ADR evaluations, assesses both of their severity and avoidability, and indicates therapeutic alternatives to suspected medications.

This is, to our knowledge, the first large multi-center and prospective study in France that evaluates the relationship between adverse drug reactions and unlicensed/ off-label drugs use in hospitalized children. The results of this study will provide more information on the prescription practice and the amplitude, nature and consequences of unlicensed/off-label drug use in hospitalized children. It will also help identify the risk factors of ADR that could be used to implement preventive actions, and guide future research in the field. An indirect benefit is represented by the increase of physicians' awareness in detecting and declaring ADRs and by communicating the results to the health professionals and to the public. This study is funded by ANSM (the French Medicine Agency).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adverse Drug Reactions in Pediatrics: Experience of a Regional Pharmacovigilance Center

NCT03316014

Child With Adverse Drug Reactions

COMPLETED

Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics

NCT00229671

Pediatric ALL

COMPLETED NA

Abdominal Pain Disorders Functional in Children: Impact of Hypno-analgesia on the Autonomic Balance

NCT02830698

Child Abdominal Pain

TERMINATED

Pharmacokinetics of Off Label Pediatric Medications

NCT01286519

Off Label Use of Medications in Pediatric Patients

RECRUITING

Safer Use of Medication in Pediatric Patients at Home

NCT04598139

Medication Errors and Other Product Use Errors and Issues

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hospitalized Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children from 0 to 15 years old \[0 ; 15\[ (including term and preterm newborn infants).
* Hospitalised for at least 3 days.
* Receiving at least one medication.

Exclusion Criteria

* Children aged 15 to 18 years old \[15 ; 18\]
* Children hospitalized for an Adverse Drug Reaction or undergoing voluntary drug detoxification.
* Children who did not take any drugs during their hospital stay.

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No